Hayward, California-based Anthera Pharmaceuticals jumped 25% to close at $3.25 per share on 10 February after the company said an independent statistician recommended continuation of a Phase III lupus clinical trial for blisibimod following an interim analysis based on the trial's new primary endpoint.
Blisibimod failed to significantly improve symptoms for patients with systemic lupus erythematosus (SLE) in a Phase IIb study, but Anthera...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?